Electroacupuncture enhances CSPCs proliferation in an FGFR4-mediated manner to ameliorate osteoarthritis-associated pain and cartilage degeneration.

Researchers investigated how electroacupuncture (EA) helps treat osteoarthritis, a common age-related joint condition that causes pain and cartilage breakdown. Using a mouse model, scientists discovered that electroacupuncture stimulates special cells in cartilage called stem/progenitor cells (CSPCs) to multiply and help repair damaged tissue. The study found that electroacupuncture treatment significantly reduced pain behaviors and slowed cartilage degeneration in mice with osteoarthritis. The beneficial effects appear to work through a specific molecular pathway involving a protein called FGFR4, which acts like a switch to activate cartilage repair cells. When researchers blocked FGFR4, the positive effects of electroacupuncture were eliminated, confirming its essential role. The treatment activates a chain reaction involving calcium signaling and other proteins (CaMKII and STAT3) that ultimately increases FGFR4 production, leading to enhanced proliferation of cartilage repair cells. This study provides important scientific evidence explaining how electroacupuncture may help people with osteoarthritis at the cellular and molecular levels. While these results are from animal studies and need confirmation in human trials, they suggest electroacupuncture could be a valuable treatment option for osteoarthritis by addressing both pain and the underlying cartilage damage. The findings are particularly relevant for aging populations where osteoarthritis is increasingly common and treatment options remain limited. If you're considering electroacupuncture for osteoarthritis, seek treatment from a licensed acupuncturist with appropriate credentials and experience in treating joint conditions.

This study investigated electroacupuncture's therapeutic mechanisms in osteoarthritis using a murine model. Researchers isolated CD44+CD90+CD45- cartilage-derived stem/progenitor cells (CSPCs) and performed bulk RNA sequencing to identify molecular pathways. Results demonstrated that EA intervention significantly ameliorated pain behaviors and cartilage degeneration while upregulating CSPC proliferation. The therapeutic effect was mediated through fibroblast growth factor receptor 4 (FGFR4), as confirmed by targeted inhibition studies using AAV-mediated gene suppression in Gremlin 1-creERT mice. Mechanistic analyses revealed EA activates the Ca2+/p-CaMKII/STAT3 signaling cascade, with STAT3 directly binding the Fgfr4 promoter to enhance expression. Intraarticular injection of FGFR4-inhibiting adenoviruses abolished EA's therapeutic benefits, establishing causality. Techniques included immunofluorescence, immunohistochemistry, Western blot, chromatin immunoprecipitation, and luciferase reporter assays. Clinical implications suggest EA promotes endogenous cartilage repair through stem cell activation, offering a mechanistic framework for treating age-related OA beyond symptomatic pain management.